CryoCor completes trial enrolment:
This article was originally published in Clinica
CryoCor has completed enrolment of more than 170 patients in a 12-month pivotal clinical study to assess the use of its cryoablation technology in atrial fibrillation. The device, also named CryoCor, was recently approved in the US for the treatment of right atrial flutter (see Clinica No 1268, p 2). The San Diego, California-based company said that it expected to file a PMA for the treatment of atrial fibrillation in late 2008, with approval anticipated in 2009.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.